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Abstract
Background
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019
(COVID-19) convalescent plasma was initiated in response to the rapid spread of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID19. While randomized clinical trials were in various stages of development and enrollment,
there was an urgent need for widespread access to potential therapeutic agents. The objective of this study is to report on the demographic, geographical, and chronological characteristics of patients in the EAP, and key safety metrics following transfusion of COVID-19
convalescent plasma.

Methods and findings

Mayo Clinic served as the central institutional review board for all participating facilities, and
any US physician could participate as a local physician–principal investigator. Eligible
patients were hospitalized, were aged 18 years or older, and had—or were at risk of progression to—severe or life-threatening COVID-19; eligible patients were enrolled through
the EAP central website. Blood collection facilities rapidly implemented programs to collect
convalescent plasma for hospitalized patients with COVID-19. Demographic and clinical
characteristics of all enrolled patients in the EAP were summarized. Temporal patternsAU
in : PerPLOSs
access to COVID-19 convalescent plasma were investigated by comparing daily and weekly
changes in EAP enrollment in response to changes in infection rate at the state level. Geographical analyses on access to convalescent plasma included assessing EAP enrollment
in all national hospital referral regions, as well as assessing enrollment in metropolitan areas
and less populated areas that did not have access to COVID-19 clinical trials. From April 3
to August 23, 2020, 105,717 hospitalized patients with severe or life-threatening COVID-19
were enrolled in the EAP. The majority of patients were
AU : IchangedMostpatientstoThemajorityofpatientsbec
60 years of age or older AU
(57.8%),
: Ichangedoldertha
were male (58.4%), and had overweight or obesity (83.8%). There was substantial inclusion
of minorities and underserved populations: 46.4% of patients were of a race other than
white, and 37.2% of patients were of Hispanic ethnicity. Chronologically and geographically,
increases in the number of both enrollments and transfusions in the EAP closely followed
confirmed infections across all 50 states. Nearly all national hospital referral regions enrolled
and transfused patients in the EAP, including both in metropolitan and in less populated
areas. The incidence of serious adverse events was objectively low (<1%), and the overall
crude 30-day mortality rate was 25.2% (95% CI, 25.0% to 25.5%). This registry study was
limited by the observational and pragmatic study design that did not include a control or
comparator group; thus, the data should not be used to infer definitive treatment effects.

Conclusions
These results suggest that the EAP provided widespread access to COVID-19 convalescent
plasma in all 50 states, including for underserved racial and ethnic minority populations. The
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study design of the EAP may serve as a model for future efforts when broad access to a
treatment is needed in response to an emerging infectious disease.

Trial registration
ClinicalTrials.gov NCT#: NCT04338360.

Author summary
Why was this study done?
• There was a public health need to provide expedited and broad access to convalescent
plasma for the treatment of coronavirus disease 2019 (COVID-19) during the early
stages of this public health emergency in the United States.
• Convalescent plasma was initially administered through regulatory pathways that
required per-patient approval, resulting in substantial administrative time.

• The Expanded Access Program AU
(EAP)
: Pleasecheckthattheeditstothesentence}TheExpandedAccessPr
was initiated to provide broad access to COVID19 convalescent plasma and to provide a framework for standardized collection of data
describing the safety profile of convalescent plasma.

What did the researchers do and find?
• The EAP provided rapid and broad access to convalescent plasma throughout the US
and some US territories and was effective at providing therapy for demographic groups
that were severely affected by COVID-19.
• In addition, the data provide evidence supporting that transfusion of convalescent
plasma is safe in hospitalized patients with COVID-19.

What do these findings mean?
• The study design of the EAP may serve as an example for future efforts in response to a
rapidly developing infectious disease when broad access to a treatment is needed in
areas and demographic groups that are often poorly represented in clinical trials.

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), spread rapidly across the United States (US) after confirmation of the first cases of COVID-19 in the US in December 2019 and January 2020 [1]. By
March of 2020, community transmission was occurring in major metropolitan areas in the
Northeast US, where hospitals became overwhelmed with admissions for severe or life-
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threatening COVID-19 [1]. Although most of those who are infected have few or no symptoms
despite high SARS-CoV-2 viral loads [2], approximately 2% to 7% [3–5] develop hypoxemia
and severe COVID-19 leading to hospitalization and the need for supplemental oxygen support [6]. Severe cases of COVID-19 can lead to respiratory failure, which is among the leading
causes of death in persons with COVID-19 [7].
The treatment of patients with COVID-19 is primarily supportive [8]. During the early
stages of this public health emergency, evidence-based treatments were few, but immunomodulatory agents and antivirals were viewed as promising therapeutic strategies for patients with
COVID-19 [9,10]. Passive immunotherapy using convalescent plasma or serum had been used
previously to treat diverse infectious diseases [11–13], including severe acute respiratory syndrome coronavirus 1 infection (SARS-CoV-1) [14]. Further, early studies undertaken during
the COVID-19 pandemic suggested the potential efficacy of convalescent plasma in the treatment of COVID-19 [15–17].
In late March and early April of 2020, COVID-19 convalescent plasma began to be administered to patients under single-patient emergency investigational new drug (eIND) applications while randomized clinical trials of COVID-19 convalescent plasma were in various
stages of development and enrollment. Neither the single eIND process nor the speed at which
clinical trials could be implemented was meeting the need to provide access to COVID-19 convalescent plasma for most patients. For example, one institution in New York City had 45
eIND applications submitted to and approved by the US Food and Drug Administration
(FDA) in a 2-week period in late March 2020 [18]. The single-patient eIND application process
requires substantial administrative support from local institutions and the US FDA, limiting
widespread access for patients to convalescent plasma [19,20]. Additionally, clinical trials often
have inclusion criteria that are restricted to a specific geographical region or disease status
(e.g., hospitalized, but not with severe disease) and have exclusion criteria (e.g., prisoners or
recipients of solid organ transplant). Thus, a different regulatory pathway for obtaining access
to COVID-19 convalescent plasma and comprehensively studying the safety of convalescent
plasma for the treatment of COVID-19 was needed.
To provide access to COVID-19 convalescent plasma treatment and provide a framework
for standardized safety data collection, Mayo Clinic initiated the Expanded Access Program
(EAP) for COVID-19 convalescent plasma. The primary objective of the EAP was to provide
access to convalescent plasma for hospitalized patients in the US with severe or life-threatening
COVID-19 [21]. The EAP started as a national registry approved to register 5,000 patients, but
due to the extraordinary national demand for COVID-19 convalescent plasma, enrollment
goals were extended in collaboration with the US FDA and the Biomedical Advanced Research
and Development Authority (BARDA), with the aim of the EAP becoming a broad national
program obviating the need for individual-patient investigational new drug (IND) applications. We herein assess the extent to which the EAP was successful in terms of providing access
to COVID-19 convalescent plasma by presenting demographic, geographical, and chronological characteristics of patients in the EAP alongside publicly available data of state-level patterns
in COVID-19. Additionally, we analyzed key safety metrics following transfusion of convalescent plasma.

Methods
As described previously [22–24], the EAP was a national registry for hospitalized patients with
COVID-19. Collaborative support was provided by the US BARDA and FDA; funding to support the study infrastructure and study-related costs at participating sites was provided under
contract from BARDA. Mayo Clinic served as the academic research organization
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coordinating the national registry. The Mayo Clinic institutional review board (IRB), the central IRB for the registry, approved the protocol (IRB #20–0033412, ClinicalTrials.gov
NCT04338360) and all amendments, and provided regulatory oversight for all sites and investigators. The principal investigator (MJJ) was the regulatory sponsor. A data and safety monitoring board oversaw the safety analyses and advised the regulatory sponsor and the Mayo
Clinic IRB on risk. Study data were deposited with the US FDA.
The study used a prospective protocol and statistical analysis plan (as previously described
[22]), with changes to both plans during the study period associated with the EAP. Full details
of the study design, conduct, oversight, and analyses are provided in the protocol and statistical
analysis plan (S1 Text). This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (S1 Checklist).

Patients
Patients were eligible for enrollment in the EAP if they were aged 18 years or older, were hospitalized with a laboratory-confirmed diagnosis of or suspected/probable infection with
SARS-CoV-2, and either had or were judged by a healthcare provider to be at high risk of progression to severe or life-threatening COVID-19. Severe COVID-19 was defined by 1 or more
of the following: dyspnea, respiratory frequency � 30/minute, blood oxygen saturation � 93%,
ratio of partial pressure of arterial oxygen to fraction of inspired oxygen < 300, and lung
infiltrates > 50% within 24 to 48 hours of hospital admission. Life-threatening COVID-19 was
defined as 1 or more of the following: respiratory failure, septic shock, and multiple organ dysfunction or failure. To maximize access to COVID-19 convalescent plasma, no exclusion criteria were used, thereby enabling access for populations of vulnerable adults who may not be
eligible for clinical trials, including pregnant women and prisoners.

Enrollment
All hospitals and acute care facilities in the US and its territories, and any physician licensed in
the US, were allowed to register for participation provided they agreed to adhere to the treatment protocol, which was available online [21], as well as US FDA and state regulations. All
patient registration was facilitated through the central study website [25]. A single consent
form, available in 8 languages, was used by all participating sites. Prior to patient enrollment,
written informed consent was obtained from the patient or a legally authorized representative,
or by means of an emergency consent process for patients in a condition that warranted this
process. Criteria for emergency consent were consistent with the federal regulations governing
emergency consent [26]. Early COVID-19 convalescent plasma safety reports and details on
convalescent plasma transfusion antibody titers have been described elsewhere [22–24].

Distribution and transfusion of COVID-19 convalescent plasma
Eligibility for donation of COVID-19 convalescent plasma was established by the US FDA. In
brief, convalescent plasma was donated by individuals with evidence of past SARS-CoV-2
infection, as determined by a positive molecular diagnostic test for COVID-19 (i.e., at time of
illness) or a positive serological test. A minimum antibody titer against SARS-CoV-2 was not
required for convalescent plasma administration under the EAP, in part because there was no
readily deployable assay early in the pandemic. Donation was required to be at least 14 days
following resolution of COVID-19 symptoms. The eligibility criteria for donation of convalescent plasma changed over the course of the EAP, including relaxation of a requirement for
negative testing (e.g., nasopharyngeal swab) for those donating less than 28 days after
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resolution of symptoms. Convalescent plasma donors had to satisfy all requirements for allogeneic
blood donation, including measures to mitigate transfusion-related acute lung injury (TRALI).
COVID-19 convalescent plasma was collected by US FDA–licensed or–registered blood
collectors (i.e., blood centers or hospital-based collection facilities) using the standard blood
collection center procedures for plasma collection that predated COVID-19. The units of convalescent plasma were labeled using a facility-specific ISBT 128 code, which enabled tracking
of the blood product from source to patient. After a patient was enrolled, convalescent plasma
was ordered directly from a participating blood collector and transfused in accordance with
the participating institutions’ transfusion guidelines. Initially, the EAP protocol restricted
transfusion to a maximum volume of 400 mL of ABO-compatible convalescent plasma. On
May 23, 2020, it became permissible to follow institutional transfusion guidelines (e.g., transfusion of group O units with low-titer anti-A), and repeated dosing of convalescent plasma was
allowed.
The units of convalescent plasma were tracked from collection through distribution and
transfusion. This allowed for comparison of patient enrollment against utilization by location
over time. The origin and the distribution of convalescent plasma were mapped using the facility identification code embedded in the ISBT 128 code label of the units of COVID-19 convalescent plasma.

Study data
Demographic and clinical characteristics of enrolled patients were collected using the Research
Electronic Data Capture (REDCap) system (version 9.1.15–10.0.33; Vanderbilt University,
Nashville, TN) [27,28]. The online case report forms were designed to optimize convenience.
Race (American Indian or Alaska Native, Asian, Black or African American, Native Hawaiian
or Other Pacific Islander, white) and ethnicity (Hispanic/Latino or not Hispanic/Latino) were
reported in categories by site personnel in a manner consistent with guidelines provided by
the US Office of Management and Budget [29].
The database was updated as needed to fulfill the requirements of the EAP IRB and the data
collection requirements of BARDA. As the original goal of data collection was to determine
safety among 5,000 patients, updates were needed to capture additional clinical data as enrollment expanded and the study progressed. Additionally, in response to surges in COVID-19
infection rates, data collection instruments were simplified by requiring less detailed demographic and clinical information about transfused patients. Enrollment into the EAP was
stopped after the US FDA issued an emergency use authorization (EUA) for COVID-19 convalescent plasma on August 23, 2020. Data clarification requests were sent to participating
investigators as needed until the database was locked to further data changes on December 16,
2020. All versions of the study protocol, case report forms with completion instructions, and
the informed consent form are publicly available on the study website [25].

COVID-19 epidemiological data sources

In order to contextualize whether the patients enrolled in the EAP were reflective of the US
population, race and ethnicity data for each state and US territory were retrieved from the US
Census Bureau [30], using the same race and ethnicity categories that were collected in the
EAP. Confirmed COVID-19 infection rates per day for each US state were obtained from the
New York Times database [31]. Hospital referral regions are regional healthcare markets
defined by where most residents within that region have their hospitalization stays. The 306
hospital referral regions in the US were retrieved from the Dartmouth Atlas of Health Care
[32]. Data on region type (metropolitan, micropolitan, or neither) AU
were: obtained
IchangedMetropolitanandlesspo
from US
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Census Bureau data [30] and the 2010 Office of Management and Budget standards that define
metropolitan and micropolitan areas based on statistical assessments [33]. Micropolitan areas
were defined as areas with a population of at least 10,000 and less than 50,000 residents. The
US regions of Northeast, South, Midwest, and West wAU
ere delineated
: IchangedNortheast;
using commonly
Southeast;
used Midwest; Sou
regions [34]. Characteristics of US hospitals were retrieved from American Hospital Directory
[35] and the Centers for Medicare & Medicaid Services [36]. The potential limitations of the
data sources are described in the Discussion.
Serious transfusion reactions. All serious transfusion reactions were reported by the
treating physicians and independently adjudicated over the course of the study by the IND
sponsor and trained designees using National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol criteria [37]. Serious transfusion reactions
were defined as transfusion-associated circulatory overload (TACO), TRALI, severe allergic
reaction, hypotensive reaction, or death. By definition, all serious transfusion reactions
occurred within 6 hours of the COVID-19 convalescent plasma transfusion. The attribution
categories used for evaluating the relatedness of serious transfusion reactions to COVID-19
convalescent plasma transfusion included unrelated, possibly related, probably related, and
definitely related. Serious transfusion reactions were collected using case report forms completed 4 hours and 7 days after transfusion, with additional forms used to report more serious
adverse event information when needed.
Statistical considerations. To provide a comprehensive report of enrollment data for the
EAP program, descriptive statistics are presented for demographic and clinical variables of
interest. To examine enrollment in the EAP over time, dot plots are used to show the number
of enrollments, for each US state individually and aggregated by region, by day of the study.
Additionally, EAP enrollment was compared to the number of confirmed COVID-19 cases
per state over the duration of the study. During the window of EAP enrollment, a moving
7-day average was calculated for daily enrollments and COVID-19 cases within each state that
enrolled more than 10 patients in total in the EAP. To compare and visualize relative patterns,
these averages were scaled between 0 (lowest cases/enrollments) and 1 (peak cases/enrollments) and overlaid on a geofaceted graph. The geofaceted graph contains
AU : Pleasecheckthattheeditstothesent
1 cell for each US
state that is placed at approximately the same location on the graph as the corresponding geographical location of the state on a map. Differences in geographical access to convalescent
plasma through the EAP were assessed by examining enrollment across micropolitan and metropolitan areas and the number of hospitals enrolling patients in each hospital referral region
in the US. Crude mortality (observed number of deaths divided by the number of transfused
patients) is presented across a range of patient and region characteristics. For this analysis,
crude mortality was summarized with 95% confidence intervals; no tests for differences
among or between levels were performed. All data were processed using R version 3.6.2.

Results
Enrolled patients
Enrolled patient characteristics. From April 3 to August 23, 2020, 105,717 hospitalized
patients with severe or life-threatening COVID-19 were enrolled in the EAP, and approximately 95,000 patients were transfused with COVID-19 convalescent plasma. The EAP halted
enrollment forthwith after the US FDA issued an EUA for COVID-19 convalescent plasma on
August 23, 2020, stating that the totality of scientific evidence indicated that convalescent
plasma was safe [23,24] and a potentially promising therapeutic treatment [38]. This authorization enabled physicians to use COVID-19 convalescent plasma without requesting eIND or
IND permission and obviated the need for access to convalescent plasma via the EAP.
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Enrolled patients’ demographic
AU : Pleasecheckthattheeditstothesentence}Enrolledpatients:::}captureyourmeani
characteristics (including age, sex, race, ethnicity) and clinical characteristics at the time of transfusion are shown in Table 1. The majority of
AUpatients
: IchangedMostpatie
were 60 years of age or older (57.8%),
AU : Ichangedolderthan60yearsofageto60yearsofageoroldertoalignwiththe
were male (58.4%), had overweight or obesity (83.8%),
and had never smoked (69.7%). There was inclusion of minorities and underserved populations; 46.4% of patients were of a race other than white, and 37.2% of patients were of Hispanic
ethnicity. Preexisting conditions present among enrolled patients, and concomitant medications, are also displayed in Table 1. Of those patients enrolled, 61.8% had severe or life-threatening COVID-19, 42.3% were in the intensive care unit (ICU), and 19.8% had received
intubation or a higher level of respiratory support at the time of transfusion. A small proportion of patients (3.9%) had no form of hospital respiratory support prior to infusion. A large
percentage of patients had dyspnea (75.7%), oxygen saturation � 93% (75.0%), and acute
respiratory failure (60.6%). Many patients were prescribed steroids (65.7%), azithromycin
(49.0%), and remdesivir (37.6%) during their hospital stay. The median number of days
between diagnosis of COVID-19 and the first transfusion was 4 days (interquartile range, 2–8
days), and nearly half of transfused patients (45.0%) received convalescent plasma within 3
days of COVID-19 diagnosis, often during hospital admission.
Geospatial patterns in enrollment. Patients were enrolled from each state in the US, the
District of Columbia, and the US territories of Puerto Rico and the US Virgin Islands
(Table 2). A large percentage of patients were enrolled in the Southern region of the US
(55.2%), and most patients enrolled in a hospital within a metropolitan area (95.2%) that was
part of a health system (85.4%) and/or was university affiliated (54.2%) (Table 1).
Patients were enrolled at 2,211 hospitals and acute care facilities across the US (Fig 1;
Table 3). The median number of patients per site was 22 (range, 1 to 1,175). While 2,722 sites
were registered, 511 (18.8%) enrolled no patients, 713 (26.2%) enrolled between 1 and 10
patients, and 1,498 (55.0%) enrolled more than 10 patients. Registered sites encompassed
nearly all hospital referral regions in the US (Fig 2). Site participation occurred both in metropolitan and non-metropolitan areas and involved different hospital types ranging from community hospitals to major teaching hospitals (Table 3).
Recognizing the disproportionate effects of the COVID-19 pandemic on minority communities [20], the EAP sought widespread access to convalescent plasma for patients. Patient
enrollment stratified
AU : Pleasecheckthattheeditstothesentence}Patientenrollment:::}captureyourmeaning:Ifnot
by race and ethnicity groups is displayed in Fig 3 and summarized in S1
Table per 100,000 people (from the US census). EAP enrollments were consistent across racial
and ethnic groups as well as across age groups (Fig 3).
Temporal patterns in enrollment. Enrollment in the EAP for convalescent plasma in
each US state on each day of the EAP is displayed in Fig 4. The individual states and regional
aggregates show clear patterns of when COVID-19 was surging during EAP enrollment. Fig 5
presents enrollment over time together with the number of active COVID-19 cases per US
state. Chronologically, increases in enrollment in the EAP closely followed individual state
infection rates. The number of patients enrolling in the EAP per 1,000 confirmed COVID-19
cases varied from 0.8 (Vermont) to 39.1 (Hawaii) across US states. The proportion that each
US region contributed to total enrollment into the EAP varied throughout the program. Fig 6
displays proportional enrollment into the EAP across time by patient symptomatology, including COVID-19 disease severity at enrollment, ICU status, and level of respiratory support
prior to COVID-19 convalescent plasma transfusion.

Transfused patients
Transfused patient characteristics. Of the 105,717 patients enrolled in the EAP, about
90% of patients (94,287 patients) were transfused with a total of 112,654 units of COVID-19
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Table 1. Characteristics and crude mortality rates of patients with COVID-19 who were enrolled in the US Expanded Access Program for convalescent plasma.
Transfused
patients

Not transfused/
unreported

All enrolled
patients

30-day crude mortality
(95% CI)a

Patient signed

65,067/94,254
(69.0)

7,482/11,406 (65.6)

72,549/105,660
(68.7)

17.93% (17.64%, 18.23%)

LAR/surrogate signed

24,634/94,254
(26.1)

3,293/11,406 (28.9)

27,927/105,660
(26.4)

42.00% (41.38%, 42.62%)

Emergency exception

4,553/94,254 (4.8)

631/11,406 (5.5)

5,184/105,660 (4.9) 38.59% (37.18%, 40.01%)

18 to 19

127/94,287 (0.1)

22/11,430 (0.2)

149/105,717 (0.1)

20 to 29

2,367/94,287 (2.5)

320/11,430 (2.8)

2,687/105,717 (2.5) 6.20% (5.30%, 7.25%)

30 to 39

5,978/94,287 (6.3)

816/11,430 (7.1)

6,794/105,717 (6.4) 7.57% (6.92%, 8.27%)

40 to 49

11,703/94,287
(12.4)

1,476/11,430 (12.9)

13,179/105,717
(12.5)

11.56% (10.99%, 12.15%)

50 to 59

19,488/94,287
(20.7)

2,301/11,430 (20.1)

21,789/105,717
(20.6)

16.66% (16.14%, 17.19%)

60 to 69

23,632/94,287
(25.1)

2,673/11,430 (23.4)

26,305/105,717
(24.9)

27.03% (26.47%, 27.60%)

70 to 79

19,351/94,287
(20.5)

2,234/11,430 (19.5)

21,585/105,717
(20.4)

36.25% (35.57%, 36.93%)

80 to 89

9,617/94,287
(10.2)

1,263/11,430 (11.0)

10,880/105,717
(10.3)

43.81% (42.82%, 44.80%)

90 to 99

1,970/94,287 (2.1)

308/11,430 (2.7)

2,278/105,717 (2.2) 47.48% (45.27%, 49.69%)

100+

54/94,287 (0.1)

17/11,430 (0.1)

71/105,717 (0.1)

40.74% (28.68%, 54.03%)

4,732/11,430 (41.4)

43,544/105,717
(41.2)

23.30% (22.88%, 23.72%)

Characteristic
Consent type

Age at enrollment (years)
8.66% (4.91%, 14.85%)

Sex
Female
Male

55,109/94,287
(58.4)

6,652/11,430 (58.2)

61,761/105,717
(58.4)

26.61% (26.24%, 26.98%)

Intersex

141/94,287 (0.1)

16/11,430 (0.1)

157/105,717 (0.1)

22.70% (16.56%, 30.28%)

Transgenderb

129/94,287 (0.1)

15/11,430 (0.1)

144/105,717 (0.1)

20.93% (14.80%, 28.74%)

Prefer not to disclose

96/94,287 (0.1)

15/11,430 (0.1)

111/105,717 (0.1)

19.79% (13.05%, 28.86%)

Underweight

1,111/91,920 (1.2)

194/10,925 (1.8)

1,305/102,845 (1.3) 33.24% (30.53%, 36.07%)

Normal weight

13,551/91,920
(14.7)

1,746/10,925 (16.0)

15,297/102,845
(14.9)

31.43% (30.65%, 32.22%)

Overweight

25,460/91,920
(27.7)

3,062/10,925 (28.0)

28,522/102,845
(27.7)

26.99% (26.45%, 27.54%)

Class 1 obesity

22,782/91,920
(24.8)

2,568/10,925 (23.5)

25,350/102,845
(24.6)

24.00% (23.45%, 24.56%)

Class 2 obesity

13,734/91,920
(14.9)

1,547/10,925 (14.2)

15,281/102,845
(14.9)

21.87% (21.19%, 22.57%)

Class 3 obesity

15,282/91,920
(16.6)

1,808/10,925 (16.5)

17,090/102,845
(16.6)

20.17% (19.54%, 20.82%)

American Indian or Alaska Native alone

1,346/94,286 (1.4)

88/11,429 (0.8)

1,434/105,715 (1.4) 27.06% (24.76%, 29.50%)

Asian alone

3,018/94,286 (3.2)

414/11,429 (3.6)

3,432/105,715 (3.2) 25.53% (24.01%, 27.12%)

Black or African American alone

16,988/94,286
(18.0)

2,237/11,429 (19.6)

19,225/105,715
(18.2)

24.71% (24.06%, 25.36%)

Native Hawaiian or Other Pacific Islander alone

549/94,286 (0.6)

56/11,429 (0.5)

605/105,715 (0.6)

16.76% (13.87%, 20.11%)

Two or more races

427/94,286 (0.5)

56/11,429 (0.5)

483/105,715 (0.5)

24.59% (20.74%, 28.89%)

White alone

50,972/94,286
(54.1)

5,715/11,429 (50.0)

56,687/105,715
(53.6)

26.09% (25.71%, 26.48%)

Other or unknown

20,986/94,286
(22.3)

2,863/11,429 (25.1)

23,849/105,715
(22.6)

23.61% (23.04%, 24.19%)

c

Weight status

Race

(Continued )
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Table 1. (Continued)
Characteristic

Transfused
patients

Not transfused/
unreported

All enrolled
patients

30-day crude mortality
(95% CI)a

Hispanic/Latino

34,807/94,287
(36.9)

4,528/11,430 (39.6)

39,335/105,717
(37.2)

24.27% (23.82%, 24.72%)

Not Hispanic/Latino

59,480/94,287
(63.1)

6,902/11,430 (60.4)

66,382/105,717
(62.8)

25.79% (25.44%, 26.14%)

O−

3,795/94,287 (4.0)

428/11,430 (3.7)

4,223/105,717 (4.0) 28.03% (26.62%, 29.48%)

O+

43,655/94,287
(46.3)

4,934/11,430 (43.2)

48,589/105,717
(46.0)

A−

3,301/94,287 (3.5)

372/11,430 (3.3)

3,673/105,717 (3.5) 27.33% (25.84%, 28.88%)

A+

28,665/94,287
(30.4)

3,217/11,430 (28.1)

31,882/105,717
(30.2)

B−

892/94,287 (0.9)

137/11,430 (1.2)

1,029/105,717 (1.0) 25.96% (23.18%, 28.93%)

B+

10,868/94,287
(11.5)

1,693/11,430 (14.8)

12,561/105,717
(11.9)

24.62% (23.82%, 25.44%)

AB−

310/94,287 (0.3)

74/11,430 (0.6)

384/105,717 (0.4)

30.74% (25.86%, 36.10%)

AB+

2,801/94,287 (3.0)

575/11,430 (5.0)

3,376/105,717 (3.2) 24.86% (23.29%, 26.50%)

April

7,130/94,287 (7.6)

1,589/11,430 (13.9)

8,719/105,717 (8.2) 36.04% (34.93%, 37.16%)

May

14,425/94,287
(15.3)

1,448/11,430 (12.7)

15,873/105,717
(15.0)

28.73% (28.00%, 29.48%)

June

16,603/94,287
(17.6)

1,362/11,430 (11.9)

17,965/105,717
(17.0)

22.30% (21.67%, 22.94%)

July

34,506/94,287
(36.6)

4,815/11,430 (42.1)

39,321/105,717
(37.2)

24.83% (24.38%, 25.29%)

August

21,623/94,287
(22.9)

2,216/11,430 (19.4)

23,839/105,717
(22.5)

22.19% (21.64%, 22.75%)

58,478/94,287
(62.0)

6,858/11,430 (60.0)

65,336/105,717
(61.8)

30.00% (29.63%, 30.38%)

35,809/94,287
(38.0)

4,572/11,430 (40.0)

40,381/105,717
(38.2)

17.41% (17.02%, 17.81%)

Current smoker

1,565/30,532 (5.1)

125/2,299 (5.4)

1,690/32,831 (5.1)

20.77% (18.83%, 22.85%)

Past smoker

7,727/30,532
(25.3)

523/2,299 (22.7)

8,250/32,831 (25.1) 32.42% (31.38%, 33.47%)

Never smoked

21,240/30,532
(69.6)

1,651/2,299 (71.8)

22,891/32,831
(69.7)

21.49% (20.94%, 22.05%)

Ethnicity

Blood type
25.21% (24.81%, 25.62%)

24.82% (24.32%, 25.32%)

Enrollment month

COVID19 severity at enrollment
Currently has severe/life-threatening COVID-19
At high risk of progression to severe/life-threatening disease
(judged by provider)
Smoking status

Highest level of hospital respiratory support prior to transfusion
None

3,613/93,430 (3.9)

3,613/93,430 (3.9)

7.48% (6.67%, 8.39%)

Oxygen supplementation

34,965/93,430
(37.4)

34,965/93,430
(37.4)

11.32% (10.99%, 11.66%)

Noninvasive positive-pressure ventilation (NIPPV)

36,350/93,430
(38.9)

36,350/93,430
(38.9)

28.37% (27.91%, 28.84%)

Mechanical ventilation/intubation

18,209/93,430
(19.5)

18,209/93,430
(19.5)

48.88% (48.15%, 49.60%)

Extracorporeal membrane oxygenation (ECMO)

293/93,430 (0.3)

293/93,430 (0.3)

31.40% (26.35%, 36.93%)

54,255/94,036
(57.7)

54,255/94,036
(57.7)

16.16% (15.85%, 16.47%)

Intensive care unit care prior to infusion
No

(Continued )
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Table 1. (Continued)
Characteristic
Yes

Transfused
patients

Not transfused/
unreported

39,781/94,036
(42.3)

All enrolled
patients

30-day crude mortality
(95% CI)a

39,781/94,036
(42.3)

37.60% (37.12%, 38.07%)

Severe COVID-19 symptomsAU : InTable1; firstcolumn : IeditedtheheadingSevereriskfactorstotwoseparateheadings : SevereCOVID

19symptomsandLife

thr

Dyspnea
No

14,007/58,478
(24.0)

1,843/6,858 (26.9)

15,850/65,336
(24.3)

37.42% (36.62%, 38.22%)

Yes

44,471/58,478
(76.0)

5,015/6,858 (73.1)

49,486/65,336
(75.7)

27.67% (27.25%, 28.09%)

No

35,838/58,478
(61.3)

3,978/6,858 (58.0)

39,816/65,336
(60.9)

28.00% (27.54%, 28.47%)

Yes

22,640/58,478
(38.7)

2,880/6,858 (42.0)

25,520/65,336
(39.1)

33.18% (32.57%, 33.80%)

No

14,489/58,478
(24.8)

1,868/6,858 (27.2)

16,357/65,336
(25.0)

33.73% (32.96%, 34.50%)

Yes

43,989/58,478
(75.2)

4,990/6,858 (72.8)

48,979/65,336
(75.0)

28.78% (28.36%, 29.20%)

No

44,020/58,478
(75.3)

4,775/6,858 (69.6)

48,795/65,336
(74.7)

27.53% (27.12%, 27.95%)

Yes

14,458/58,478
(24.7)

2,083/6,858 (30.4)

16,541/65,336
(25.3)

37.53% (36.74%, 38.32%)

No

36,930/58,478
(63.2)

4,017/6,858 (58.6)

40,947/65,336
(62.7)

28.05% (27.60%, 28.52%)

Yes

21,548/58,478
(36.8)

2,841/6,858 (41.4)

24,389/65,336
(37.3)

33.35% (32.72%, 33.99%)

No

23,396/58,478
(40.0)

2,323/6,858 (33.9)

25,719/65,336
(39.4)

20.49% (19.97%, 21.01%)

Yes

35,082/58,478
(60.0)

4,535/6,858 (66.1)

39,617/65,336
(60.6)

36.36% (35.85%, 36.86%)

No

54,554/58,478
(93.3)

6,160/6,858 (89.8)

60,714/65,336
(92.9)

28.58% (28.20%, 28.96%)

Yes

3,924/58,478 (6.7)

698/6,858 (10.2)

4,622/65,336 (7.1)

49.86% (48.29%, 51.43%)

No

53,537/58,478
(91.6)

5,968/6,858 (87.0)

59,505/65,336
(91.1)

28.27% (27.89%, 28.65%)

Yes

4,941/58,478 (8.4)

890/6,858 (13.0)

5,831/65,336 (8.9)

48.84% (47.45%, 50.24%)

No

34,353/41,141
(83.5)

2,503/2,940 (85.1)

36,856/44,081
(83.6)

25.68% (25.22%, 26.15%)

Yes

6,788/41,141
(16.5)

437/2,940 (14.9)

7,225/44,081 (16.4) 32.08% (30.98%, 33.20%)

Respiratory frequency � 30/minute

Blood oxygen saturation � 93%

PaO2:FiO2 ratio < 300

Lung infiltrates > 50% within 24 to 48 hours

Life-threatening COVID-19 symptoms
Respiratory failure

Septic shock

Multiple organ dysfunction or failure

Preexisting conditions
History of lung disease (e.g., COPD, lung cancer)

Cancer other lung cancerAU : InTable1; firstcolumn : IchangedCancerotherthanabovetoCancerotherthanlungcancer:Ifthisisnotcorrect; pleaseeditasnecessary:
No

39,242/41,141
(95.4)

2,771/2,940 (94.3)

42,013/44,081
(95.3)

26.35% (25.92%, 26.79%)
(Continued )
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Table 1. (Continued)
Characteristic

Transfused
patients

Not transfused/
unreported

All enrolled
patients

30-day crude mortality
(95% CI)a

1,899/41,141 (4.6)

169/2,940 (5.7)

2,068/44,081 (4.7)

34.65% (32.54%, 36.82%)

No

20,771/41,141
(50.5)

1,637/2,940 (55.7)

22,408/44,081
(50.8)

21.51% (20.96%, 22.08%)

Yes

20,370/41,141
(49.5)

1,303/2,940 (44.3)

21,673/44,081
(49.2)

32.06% (31.43%, 32.71%)

No

40,803/41,141
(99.2)

2,927/2,940 (99.6)

43,730/44,081
(99.2)

26.73% (26.31%, 27.17%)

Yes

338/41,141 (0.8)

13/2,940 (0.4)

351/44,081 (0.8)

26.92% (22.47%, 31.89%)

No

40,781/41,141
(99.1)

2,925/2,940 (99.5)

43,706/44,081
(99.1)

26.68% (26.25%, 27.11%)

Yes

360/41,141 (0.9)

15/2,940 (0.5)

375/44,081 (0.9)

33.61% (28.93%, 38.64%)

No

39,592/41,141
(96.2)

2,858/2,940 (97.2)

42,450/44,081
(96.3)

26.42% (25.98%, 26.85%)

Yes

1,549/41,141 (3.8)

82/2,940 (2.8)

1,631/44,081 (3.7)

34.93% (32.59%, 37.33%)

No

24,641/41,141
(59.9)

1,828/2,940 (62.2)

26,469/44,081
(60.0)

24.28% (23.75%, 24.82%)

Yes

16,500/41,141
(40.1)

1,112/2,940 (37.8)

17,612/44,081
(40.0)

30.40% (29.70%, 31.11%)

No

38,129/40,880
(93.3)

2,734/2,925 (93.5)

40,863/43,805
(93.3)

26.99% (26.55%, 27.44%)

Yes

2,751/40,880 (6.7)

191/2,925 (6.5)

2,942/43,805 (6.7)

23.88% (22.33%, 25.51%)

No

37,351/40,880
(91.4)

2,702/2,925 (92.4)

40,053/43,805
(91.4)

26.97% (26.52%, 27.42%)

Yes

3,529/40,880 (8.6)

223/2,925 (7.6)

3,752/43,805 (8.6)

24.77% (23.38%, 26.22%)

No

20,836/40,880
(51.0)

1,499/2,925 (51.2)

22,335/43,805
(51.0)

26.85% (26.25%, 27.45%)

Yes

20,044/40,880
(49.0)

1,426/2,925 (48.8)

21,470/43,805
(49.0)

26.71% (26.10%, 27.33%)

No

25,269/40,880
(61.8)

2,076/2,925 (71.0)

27,345/43,805
(62.4)

28.61% (28.06%, 29.17%)

Yes

15,611/40,880
(38.2)

849/2,925 (29.0)

16,460/43,805
(37.6)

23.81% (23.15%, 24.49%)

No

14,036/40,880
(34.3)

1,005/2,925 (34.4)

15,041/43,805
(34.3)

23.45% (22.75%, 24.15%)

Yes

26,844/40,880
(65.7)

1,920/2,925 (65.6)

28,764/43,805
(65.7)

28.52% (27.99%, 29.07%)

33,557/40,880
(82.1)

2,380/2,925 (81.4)

35,937/43,805
(82.0)

25.14% (24.68%, 25.60%)

Yes
History of cardiovascular conditions

HIV-positive

HCV-positive

On immunosuppressive therapy

Diabetes

Medications during hospital stay
ARB

ACE inhibitor

Azithromycin

Remdesivir

Steroids

Hydroxychloroquine and/or chloroquine
No

(Continued )
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Table 1. (Continued)
Characteristic

Transfused
patients

Not transfused/
unreported

All enrolled
patients

7,323/40,880
(17.9)

545/2,925 (18.6)

7,868/43,805 (18.0) 34.31% (33.23%, 35.40%)

Midwest

13,454/94,287
(14.3)

1,423/11,430 (12.4)

14,877/105,717
(14.1)

22.27% (21.58%, 22.98%)

Northeast

10,372/94,287
(11.0)

1,173/11,430 (10.3)

11,545/105,717
(10.9)

33.25% (32.35%, 34.16%)

South

52,178/94,287
(55.3)

6,151/11,430 (53.8)

58,329/105,717
(55.2)

24.68% (24.31%, 25.05%)

West

18,103/94,287
(19.2)

2,636/11,430 (23.1)

20,739/105,717
(19.6)

24.28% (23.66%, 24.91%)

US territory

180/94,287 (0.2)

47/11,430 (0.4)

227/105,717 (0.2)

37.99% (31.20%, 45.28%)

Metropolitan

89,837/94,287
(95.3)

10,790/11,430 (94.4)

100,627/105,717
(95.2)

25.37% (25.09%, 25.66%)

Micropolitan

3,888/94,287 (4.1)

565/11,430 (4.9)

4,453/105,717 (4.2) 22.52% (21.24%, 23.86%)

Neither

562/94,287 (0.6)

75/11,430 (0.7)

637/105,717 (0.6)

20.68% (17.52%, 24.25%)

No

78,232/93,166
(84.0)

9,699/11,328 (85.6)

87,931/104,494
(84.1)

25.09% (24.79%, 25.39%)

Yes

14,934/93,166
(16.0)

1,629/11,328 (14.4)

16,563/104,494
(15.9)

26.18% (25.48%, 26.89%)

No

89,246/93,166
(95.8)

10,731/11,328 (94.7)

99,977/104,494
(95.7)

25.28% (25.00%, 25.57%)

Yes

3,920/93,166 (4.2)

597/11,328 (5.3)

4,517/104,494 (4.3) 24.87% (23.54%, 26.25%)

No

13,177/93,166
(14.1)

2,107/11,328 (18.6)

15,284/104,494
(14.6)

23.95% (23.22%, 24.68%)

Yes

79,989/93,166
(85.9)

9,221/11,328 (81.4)

89,210/104,494
(85.4)

25.48% (25.18%, 25.79%)

No

66,531/90,463
(73.5)

8,932/11,008 (81.1)

75,463/101,471
(74.4)

25.07% (24.74%, 25.40%)

Yes

23,932/90,463
(26.5)

2,076/11,008 (18.9)

26,008/101,471
(25.6)

25.66% (25.11%, 26.21%)

No

42,074/93,166
(45.2)

5,763/11,328 (50.9)

47,837/104,494
(45.8)

24.28% (23.87%, 24.70%)

Yes

51,092/93,166
(54.8)

5,565/11,328 (49.1)

56,657/104,494
(54.2)

26.07% (25.69%, 26.45%)

Yes

30-day crude mortality
(95% CI)a

Census region or territory

Micro/metropolitan

Rural referral center

Sole community hospital

Part of a health system

Major teaching hospital (member of COTH)

University affiliated

All values are presented as number/total number (percent).
a

Crude mortality is shown for transfused patients only; 95% confidence intervals (CIs) were estimated using binomial proportions via the Wilson method.
Transgender is a gender-specific term (as opposed to a sex-specific term).

b
c

Weight status based on BMI. Underweight: below 18.5 kg/m2; normal weight: 18.5–24 kg/m2; overweight: 25–29 kg/m2; class 1 obesity: 30–34 kg/m2; class 2 obesity:

35–39 kg/m2; class 3 obesity: 40+ kg/m2.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; COTH, Council of Teaching Hospitals;
HCV, hepatitis C virus; LAR, legally authorized representative; PaO2:FiO2, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen.
https://doi.org/10.1371/journal.pmed.1003872.t001
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Table 2. Tabular summaries of patient enrollment in the US Expanded Access Program (EAP) for convalescent plasma and US COVID-19 cases during the EAP
enrollment period, stratified by US state or territory, ordered by enrollments per 1,000 COVID-19-positive casesAU
. : PleasecheckthattheeditstothecolumnheadsinTable2capturey
State or
territory

EAP summaries

Population and COVID-19-positive ratios

Enrolling
sites

Enrolled patients
(N = 105,717)

Transfused patients
(N = 94,287)

Population COVID19-positive cases per
enrollment

Enrollments per
10,000 people

Enrollments per 1,000
COVID-19-positive cases

Hawaii

7

320

316

25.6

2.3

39.1

South Carolina

37

3,971

3,529

29.6

7.7

33.7

South Dakota

6

427

409

31.3

4.8

31.9

Texas

220

19,378

17,518

32.8

6.7

30.5

District of
Columbia

9

349

278

38.4

4.9

26.0

Oklahoma

26

1,416

1,325

41.0

3.6

24.4

Delaware

4

373

367

45.7

3.8

21.9

Georgia

73

5,423

4,919

46.0

5.1

21.7

Connecticut

23

1,022

929

48.3

2.9

20.7

Florida

158

12,575

11,222

49.0

5.9

20.4

Iowa

35

1,298

1,221

49.8

4.1

20.1

Arizona

41

3,960

3,678

50.6

5.4

19.8

North Dakota

7

226

216

51.7

3.0

19.4

Alabama

35

2,409

2,016

51.9

4.9

19.3

Nevada

19

1,302

1,127

52.3

4.2

19.1

Indiana

64

1,745

1,609

53.7

2.6

18.6

Montana

8

133

127

54.3

1.2

18.4

Ohio

77

2,184

2,007

55.2

1.9

18.1

New Hampshire

8

123

90

55.8

0.9

17.9

Kentucky

40

882

834

56.9

2.0

17.6

Tennessee

50

2,590

2,443

57.7

3.8

17.3

New Mexico

12

430

412

58.1

2.1

17.2

Maryland

42

1,815

1,594

58.8

3.0

17.0

California

235

11,874

10,079

59.2

3.0

16.9

Mississippi

19

1,380

1,313

59.3

4.6

16.9

Kansas

22

703

610

61.0

2.4

16.4

New Jersey

66

2,767

2,451

62.0

3.1

16.1

Missouri

41

1,349

1,264

62.8

2.2

15.9

Wisconsin

60

1,191

1,098

66.5

2.0

15.0

Nebraska

16

505

468

67.4

2.6

14.8

Virginia

51

1,748

1,481

68.1

2.0

14.7

Maine

9

61

57

68.6

0.5

14.6

Pennsylvania

90

1,928

1,700

69.0

1.5

14.5

Minnesota

34

1,049

1,007

71.7

1.9

13.9

Illinois

92

3,135

2,709

73.6

2.5

13.6

Washington

34

939

878

76.8

1.2

13.0

New York

109

4,489

4,143

79.1

2.3

12.6

Oregon

16

319

289

81.5

0.8

12.3

Colorado

26

645

627

84.4

1.1

11.8

Utah

8

593

574

86.3

1.8

11.6

Rhode Island

8

247

241

86.6

2.3

11.6

Louisiana

44

1,548

1,351

92.0

3.3

10.9

North Carolina

56

1,771

1,629

94.0

1.7

10.6
(Continued )
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Table 2. (Continued)
State or
territory

EAP summaries
Enrolling
sites

Population and COVID-19-positive ratios

Enrolled patients
(N = 105,717)

Transfused patients
(N = 94,287)

Population COVID19-positive cases per
enrollment

Enrollments per
10,000 people

Enrollments per 1,000
COVID-19-positive cases

Michigan

61

1,065

869

97.5

1.1

10.3

West Virginia

11

102

88

98.6

0.6

10.1

Alaska

3

59

58

100.5

0.8

9.9

Arkansas

16

599

500

101.2

2.0

9.9

Virgin Islands

2

9

6

123.2

0.8

8.1

Massachusetts

36

907

790

133.2

1.3

7.5

Puerto Rico

30

218

181

151.0

0.7

6.6

Idaho

10

156

131

202.5

0.9

4.9

Wyoming

4

9

9

411.6

0.2

2.4

Vermont

1

1

1

1,303.0

0.0

0.8

https://doi.org/10.1371/journal.pmed.1003872.t002

convalescent plasma. As shown in Table 1, demographic and clinical characteristics at the time
of transfusion were comparable between enrolled patients and transfused patients. Similarly,
the subset of about 10% of patients (11,430 patients) who were enrolled in the EAP and not
transfused with COVID-19 convalescent plasma was comparable to both enrolled patients and
transfused patients.
Collection, distribution, and utilization of COVID-19 convalescent plasma. COVID19 convalescent plasma AU
was :distributed
Pleasecheckthattheeditstothesentence}COVID
by 313 individual collection facilities (as19convalescentplasma:::
represented
by facility identification numbers) that were situated over a broad geography in the US
(Table 4), with collection centers in the South (35.8%), Midwest (25.6%), Northeast (18.5%),
and West (18.5%). Given the geographical diversity of the participating blood collection centers, COVID-19 convalescent plasma was able to be transfused in close proximity to collection.
The median distance between plasma collection or manufacturing center and transfusing hospital was 133 miles; 75% of all plasma units were transfused within 728 miles of the collection
or manufacturing center. Resource sharing with parts of the country where collection sites
were few resulted in approximately 20% of all plasma units traveling 1,000 miles or more prior
to transfusion (Fig 7). Most of the overall COVID-19 convalescent plasma utilization was in
the South (55.3%) and West (19.2%) geographical regions (Table 1; Fig 7). The states with the
highest number of transfused patients were Texas (17,518), Florida (11,222), California
(10,079), Georgia (4,919), New York (4,143), and Arizona (3,678) (Table 2).
Serious transfusion reactions. Key serious adverse events related to the transfusion of
COVID-19 convalescent plasma are reported in Fig 8 and S2 Table. Our report is not a comprehensive summary of all risks associated with hospitalization for severe or life-threatening
COVID-19. After adjudication, 597 serious adverse events were classified as related to convalescent plasma transfusion (<1% of all transfusions). TACOAU
, TRALI,
: Pleasecheckthattheeditstothesentence}
and severe allergic events
were deemed “probably” or “definitely” related to convalescent plasma transfusion for most
events, whereas hypotensive reactions were deemed “possibly” related in most cases. A broad
grouping of TACO/TRALI was used to categorize events that initiated in close temporal proximity to the transfusion (within approximately 6 hours), with a broad clinical differential that
most closely favored a diagnosis of TACO or TRALI.
Crude mortality among transfused patients. Mortality within 30 days of convalescent
plasma transfusion was 25.2% (95% CI, 25.0% to 25.5%; Table 1). Crude mortality rates of
transfused patients stratified by demographic characteristics, COVID-19 symptomatology,
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Fig 1. Participation in the US Expanded Access Program (EAP) for convalescent plasma. Choropleth map displaying the number of cumulatively enrolled
patients in the EAP within each state of the US and participating territories, with lower enrollment values displayed in a lighter shade of blue and higher
enrollment values displayed in a darker shade of blue. Registered acute care facilities are represented as filled yellow circles, with circle size corresponding to the
number of registered facilities within the county. Blood collection centers are represented as filled red diamonds. All sites with registered patients were
included. The choropleth map does not display Guam or the Northern Mariana Islands. The base layer of the geographical map was created using geographical
data retrieved from the US Census Bureau (https://www2.census.gov/geo/tiger/TIGER2019/STATE/). No copyrighted material was used.
https://doi.org/10.1371/journal.pmed.1003872.g001

preexisting health conditions, concomitant medications, and other relevant clinical variables
are displayed in Table 1. Crude mortality was 6.2% (95% CI, 5.3% to 7.3%) among transfused
patients aged 20 to 29 years and 47.5% (95% CI, 45.3% to 49.7%) among patients aged 90 to 99
years. Crude mortality was 23.3% (95% CI, 22.9% to 23.7%) among females and 26.6% (95%
CI, 26.2% to 27.0%) among males.

Discussion
Principal findings
The US EAP successfully provided access to COVID-19 convalescent plasma to over 105,000
patients, of whom nearly 95,000 patients were transfused with convalescent plasma over the
course of 5 months. The EAP provided an efficient model for population-wide procurement,
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Table 3. Characteristics of sites that enrolled patients in the US Expanded Access Program (EAP) for convalescent
plasmaAU
. : InTable3 : IchangedtheheadingforthesecondcolumnfromOveralltoNumberofsites=totalnumberðpercentÞ:Ifthisisnotcor
Characteristic

Number of sites/total number (percent)

Census region or territory
Midwest

515/2,211 (23.3%)

Northeast

350/2,211 (15.8%)

South

891/2,211 (40.3%)

West

423/2,211 (19.1%)

US territory

32/2,211 (1.4%)

Micro/metropolitan
Metropolitan

1,903/2,211 (86.1%)

Micropolitan

243/2,211 (11.0%)

Neither

65/2,211 (2.9%)

Urban/rural classification
Rural

595/2,081 (28.6%)

Urban

1,486/2,081 (71.4%)

Sole community hospital
No

1,975/2,174 (90.8%)

Yes

199/2,174 (9.2%)

Rural referral center
No

1,824/2,174 (83.9%)

Yes

350/2,174 (16.1%)

Major teaching hospital (member of COTH)
No

1,598/2,042 (78.3%)

Yes

444/2,042 (21.7%)

University affiliated
No

1,120/2,174 (51.5%)

Yes

1,054/2,174 (48.5%)

COTH, Council of Teaching Hospitals.
https://doi.org/10.1371/journal.pmed.1003872.t003

distribution, and infusion of convalescent plasma under a research protocol in a time of crisis.
At its conclusion, the program was responsible for the largest number of transfusions of convalescent plasma for a single infectious disease to date. The EAP was initiated to respond to an
emerging public health crisis. Both the scale and speed of execution of the program were notable: Over 25,000 hospitalized patients with COVID-19 were transfused with convalescent
plasma within the first 11 weeks following the program’s inception. Access to convalescent
plasma closely kept pace with increases in confirmed US COVID-19 infections per state over
time, and there was substantial inclusion of vulnerable racial and ethnic minority populations.
Geographically, enrollment in the EAP occurred in all US states, the District of Columbia, and
the US territories of Puerto Rico and the US Virgin Islands. Patients were enrolled from all but
5 of the US national hospital referral regions, and substantial enrollment occurred in both metropolitan and non-metropolitan areas.
The rate of serious transfusion reactions was objectively low. The crude 30-day mortality
rate in this high-risk patient population was 25.2%. Despite the potential risks associated with
plasma transfusion in critically ill patients, these data provide evidence supporting the safety of
COVID-19 convalescent plasma.
Demographic, chronological, and geographical characteristics of patients enrolled in
the EAP. Demographic characteristics of the complete enrolled EAP cohort showed
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Fig 2. Participation of acute care facilities in the US Expanded Access Program (EAP) for convalescent plasma stratified by US hospital referral region.
Choropleth map displaying the number of participating acute care facilities that enrolled patients in the EAP within each hospital referral region—a
geographical region that represents a catchment region of patients who get healthcare at similar facilities. Lower numbers of participating acute care facilities
are displayed in a lighter hue of blue, and higher numbers of participating acute care facilities are displayed in a darker hue of blue. Hospital referral regions
with 0 participating acute care facilities are displayed in grey. Hospital referral regions are not defined in US territories; thus, the choropleth map does not
display data from Puerto Rico, the US Virgin Islands, Guam, or the Northern Mariana Islands. The base layer of the geographical map was retrieved from the
Dartmouth Atlas Project (https://data.dartmouthatlas.org/supplemental/#boundaries) [32].
https://doi.org/10.1371/journal.pmed.1003872.g002

Fig 3. Patient enrollment in the US Expanded Access Program (EAP) stratified by age, race, and ethnicity group, per 100,000 people (from the US
census). AU
The: length
PleasecheckthattheeditstothetitleofFig3captureyourmeaning:Ifnot;
of each colored bar is proportional to the number of patients pleaseprovidecorrectwording:
enrolled in the US EAP within the identified age group (years) and race or
ethnicity category. The patient enrollment values are presented relative to analogous categorical data retrieved from the US Census Bureau. Am. Indian & AK
Native, American Indian or Alaska Native; NHPI, Native Hawaiian or Other Pacific Islander.
https://doi.org/10.1371/journal.pmed.1003872.g003
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Fig 4. Daily patient enrollment in the US Expanded Access Program. Each circle AU
represents
: PleasecheckthattheeditstothelegendforFig4captureyourmeaning:Ifanyeditsareinco
1 day in which at least 1 patient was enrolled within the
indicated US state or region. Grey circles represent daily US state enrollments, and tan circles represent daily US region enrollments. The size of the circle
corresponds to the number of daily enrollments within the specified US state or region. States are ordered alphabetically within each US region, followed by the
aggregate for each region.
https://doi.org/10.1371/journal.pmed.1003872.g004

substantial enrollment among patients 60 years of age or older (57.8%),
AU : Ichangedovertheageof
male patients (58.4%),
60to60yearso
patients of African American or Black race (18.2%), and patients of Hispanic or Latino ethnicity (37.2%). African American or Black race and Hispanic or Latino ethnicity make up 13.4%
and 18.5% of the US population, respectively [30]. Previous studies have found that older
[39,40], male [40], African American or Black race [39,41,42], and Hispanic or Latino [42]
individuals are at higher risk of hospitalization for severe or life-threatening COVID-19. The
presented enrollment results from the EAP highlight that this program was able to provide
access to COVID-19 convalescent plasma to demographic groups that have experienced the
largest disease burden from the US COVID-19 epidemic.
Participation in the EAP (both enrollments and transfusions) per day closely tracked the
number of cases reported by state as the COVID-19 epidemic developed. Participation during
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Fig 5. Daily rates of confirmed COVID-19 infections and patient enrollment in the US Expanded Access Program (EAP). Chronological line charts
represent the daily number of statewide confirmed COVID-19 infections and EAP patient enrollments sequentially arranged in a geofaceted depiction of the
US. Daily rates are presented as a moving average across 7 days, scaled between 0 (least cases/enrollments) and 1 (most cases/enrollments) for any day in each
state. Vertical dashed grey lines represent the start date of the EAP (April 3, 2020). Values in the lower left corner of each panel indicate the scaling factor
between the 2 plots (cases/enrollments), which approximates the number of COVID-19 cases that contributed to 1 enrollment in the EAP. EAP enrollment
data are not presented for Vermont or Wyoming because total enrollments were not greater than 10 patients. DC, District of Columbia.
https://doi.org/10.1371/journal.pmed.1003872.g005

April and May 2020 was high in Northeastern states, whereas in July and August participation
peaked in the Southern region AU
of mainland
: IchangedSoutheastandSouthwestregionstoSouthernregion:Ifthisedit
US, in line with the development of “hotspots” in
these regions over time [43]. An increase in enrollment in Midwestern states was observed
during August 2020, and this increase was also closely associated with an increase in confirmed
COVID-19 cases in that region. Although there was widespread participation across US states
and territories, there were fewer than 10 patients enrolled in both Vermont (n = 1) and Wyoming (n = 9), representing a small fraction of the total COVID-19 cases in those states. Given
that there were no registered clinical trials involving COVID-19 convalescent plasma in these
2 states during the time of the EAP, there may have been regulatory or administrative barriers
to participation in trials involving experimental therapeutics for COVID-19.
The EAP data reveal a gap between the number of enrolled and the number of transfused
patients, particularly during the initial peak of each “wave” of the COVID-19 pandemic. This
gap AU
appears
: Pleasecheckthattheeditstothesentence}Thisgap:::}captureyourmeaning:Ifnot;
to represent the few days required to establish the local/regional infrastructure
pleaseprovidecor
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Fig 6. Daily patient enrollment in the US Expanded Access Program (EAP) relative to COVID-19 patient symptomatology. Stacked area chart displaying
daily rates of patient enrollment in the EAP as a proportion of the sum total daily enrollment stratified by patient symptomatology, including 2 categories of
COVID-19 disease severity, dichotomous representation of intensive care unit (ICU) status, and categorical level of respiratory support prior to COVID-19
convalescent plasma transfusion (none, oxygen supplementation, noninvasive positive-pressure ventilation [NIPPV], mechanical ventilation, or extracorporeal
membrane oxygenation [ECMO]). Only patients who received a COVID-19 convalescent plasma transfusion are included in the 2 rightmost panels.
https://doi.org/10.1371/journal.pmed.1003872.g006

necessary to set up the collection and transfusion of convalescent plasma. Convalescent plasma
was also shared between regions when the epidemic intensified in a certain region.
Strengths and limitations. The US EAP for COVID-19 convalescent plasma aimed to
provide access to a treatment possibly providing benefit. Many of the trials of convalescent
plasma experienced delays due to the unique challenges inherent to undertaking complex
research during a public health crisis [44]. The EAP rapidly provided access to important
information on the safety of COVID-19 convalescent plasma [23,24] while also providing signals of efficacy through exploratory analyses [22]. One of the federal requirements for an EAP
is that it should not interfere with pivotal trials [45]. The EAP for COVID-19 convalescent
plasma continuously transmitted data to the US FDA for ongoing evaluation of consistency
with federal requirements for an EAP, and the program was not discontinued until the issuance of an EUA, which obviated the need for a convalescent plasma EAP.
Numerous challenges were encountered during the development and implementation of
this national registry. In the context of competing demands on healthcare resources during the
COVID19 pandemic [46], this national registry used a modern design with creative solutions
to overcome the epidemiological and logistical challenges of the pandemic [47]. Creative solutions included a central academic IRB for oversight, streamlined registration for sites and physicians, simple online data collection forms, a robust support center that was accessible via
email or telephone, minimal patient exclusion criteria, few restrictions on concomitant therapies, and no initiation or monitoring site visits. Several important limitations resulted from
this design, however, including impact on data collection during “waves” (i.e., large increases
in the number of cases of COVID-19 in the US) of the pandemic, unavailable data due to
abridged data collection forms, and missing data due to the nature of a national registry. Additionally, the EAP was designed to provide access to convalescent plasma at hospitals and acute
care facilities that were not already part of a clinical trial or did not have the infrastructure to
support complex clinical trials. This registry also did not require training of the local investigators or study team members. This pragmatic approach did not ensure the highest quality of
data nor completeness of data.
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Table 4. Summary of blood collection facilities, donations, and plasma distribution supporting the US Expanded
Access Program (EAP) for convalescent plasmaAU
. : PleasecheckthattheeditstothecolumnheadsinTable4captureyourmeaning:Ifn
Measure

Number or number/total number (percent)

Transfusions by the numbers
Patients transfused

94,287

Recorded transfusions

100,829

Total units given

112,654

Volume of plasma transfused (L)

25,223

Unique blood banks (FIN-based)

313

Blood collection center region/territory
Midwest

80/313 (25.6%)

Northeast

58/313 (18.5%)

South

112/313 (35.8%)

West

58/313 (18.5%)

US territory

5/313 (1.6%)

Travel distance of plasma donation to transfusion location (miles)
0 to 9

20,846/112,605 (18.5%)

10 to 49

20,399/112,605 (18.1%)

50 to 99

10,408/112,605 (9.2%)

99 to 149

6,599/112,605 (5.9%)

150 to 499

19,822/112,605 (17.6%)

500 to 999

11,483/112,605 (10.2%)

1,000 to 1,999

18,850/112,605 (16.7%)

2,000+

4,198/112,605 (3.7%)

Units donated per region (subgrouped by receiving location)
Midwest
Midwest

11,693/16,894 (69.2%)

South

3,176/16,894 (18.8%)

West

1,817/16,894 (10.8%)

Northeast

200/16,894 (1.2%)

US territory

8/16,894 (0.0%)

Northeast
South

18,822/38,528 (48.9%)

Northeast

11,752/38,528 (30.5%)

West

4,175/38,528 (10.8%)

Midwest

3,713/38,528 (9.6%)

US territory

66/38,528 (0.2%)

South
South

38,347/39,368 (97.4%)

Midwest

503/39,368 (1.3%)

Northeast

273/39,368 (0.7%)

West

236/39,368 (0.6%)

US territory

9/39,368 (0.0%)

West
West

16,372/17,629 (92.9%)

South

776/17,629 (4.4%)

Midwest

380/17,629 (2.2%)

Northeast

97/17,629 (0.6%)

US territory

4/17,629 (0.0%)
(Continued )
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Table 4. (Continued)
Measure

Number or number/total number (percent)

US territory
US territory

184/186 (98.9%)

South

2/186 (1.1%)

FIN, facility identification number.
https://doi.org/10.1371/journal.pmed.1003872.t004

Implications for clinical practice and public policy. The success of the EAP in providing
rapid access to convalescent plasma, combined with evidence supporting the safety of
COVID-19 convalescent plasma, indicates that convalescent plasma is a “common sense”

Fig 7. Travel paths of units of convalescent plasma from blood collection centers to sites of plasma transfusion within the contiguous US in the
Expanded Access Program (EAP) for convalescent plasma. Map displaying the distance and direction of travel of convalescent plasma units in support of the
EAP, with the thickness of each colored line directly proportional to the number of convalescent plasma units represented. Lines colored in blue represent a
travel direction of east to west (e.g., New York City, NY, to Los Angeles, CA), and lines colored in orange represent a travel direction of west to east (e.g.,
Minneapolis, MN, to Tampa, FL). The US FDA–licensed or–registered blood collection facilities supplying plasma are presented as filled red diamonds, and
acute care facilities are presented as filled yellow circles. The map does not display data from noncontiguous US locations, including facilities in Puerto Rico,
Hawaii, and Alaska. The base layer of the geographical map was created using geographical data retrieved from the US Census Bureau (https://www2.census.
gov/geo/tiger/TIGER2019/STATE/). No copyrighted material was used.
https://doi.org/10.1371/journal.pmed.1003872.g007
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Fig 8. Chord diagram of the attributions associated with serious transfusion reactions. Attribution to a category of relatedness is depicted by a line
connecting from each serious transfusion reaction type. The width of each line and the circumferential axis indicate the number of patients in each combined
serious transfusion reaction and relatedness category group. Other transfusion reactions that were adjudicated to be possibly related to the transfusion (n = 3)
included leukomoid reaction (n = 1), pulmonary embolism (n = 1), and red cell dilution (n = 1). TACO, transfusion-associated circulatory overload; TRALI,
transfusion-related acute lung injury.
https://doi.org/10.1371/journal.pmed.1003872.g008

therapeutic that can be mobilized for future infectious disease outbreaks using the EAP methods as a model. In this regard it is noteworthy, given that COVID-19 convalescent plasma clinical trials were limited to only a few institutions, that most patients treated with plasma would
have had no access without the EAP or single-patient eIND applications. The high use of convalescent plasma within the EAP indicates a high level of acceptance for this therapy by
patients and frontline physicians despite the absence of high-quality data for its clinical efficacy. The EAP design was particularly effective in providing access to a potentially effective
treatment in minority demographic groups and rural areas that are often underrepresented in
US randomized controlled trials [48,49].
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Conclusion
The EAP provided rapid and broad access to convalescent plasma throughout the US and
some US territories and was effective at providing therapy for demographic groups that were
severely affected by COVID-19. Over time, the EAP provided access to convalescent plasma in
response to sudden and exponential changes in SARS-CoV-2 infection rates. Data gathered
from the EAP established that COVID-19 convalescent plasma was generally safe [23,24], and
the EAP provided key efficacy data that were an important component of the scientific evidence considered by the US FDA in the decision to issue an EUA [22] for convalescent plasma
in the treatment of hospitalized adults with COVID-19. Hence, this program established that it
is possible to obtain relevant and actionable safety and efficacy data during pandemic conditions. The efficient study design of the EAP may serve as an example for future efforts when
broad access to a treatment is needed in response to a rapidly developing infectious disease,
providing access in areas typically underrepresented in clinical studies and thereby allowing
capture of demographic groups that are often poorly represented in clinical trials.
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